Merck (MRK) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of ...

Through the five-year initiative, the Merck Foundation will provide grants to 11 organizations working to improve health outcomes in places where timely access to cardiovascular care is a challenge.

Despite Merck & Co.’s underperformance relative to the broader market over the past year, Wall Street analysts remain ...

Merck & Co. began Tuesday with back-to-back deals, revealing separate agreements to pay $150 million upfront for full control of an early-phase asset and pocket $700 million to support an expansive ...

Merck & Co posted higher third-quarter revenue on Thursday, as growth from its blockbuster cancer drug Keytruda offset ...

Wondering if Merck stock is truly a bargain or just priced for perfection? You are not alone. Let's dig into what the numbers ...

Merck & Co. is taking full control of MK-8690, an investigational drug targeting inflammatory bowel diseases that was part of the drugmaker's $10.8 billion acquisition of Prometheus Biosciences in ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

Merck & Co Inc <a href=" target="_blank">(MRK.N) has agreed to acquire drugmaker OncoImmune in a deal that will give it control of a drug that could help ease symptoms and reduce deaths in patients ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the company inked with Austria-based drug delivery technology maker Cyprumed.

Discover Merck & Co., Inc.'s Q3 earnings outlook as Keytruda's patent nears expiry. Click for my updated look at MRK stock ...